期刊
CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS
卷 13, 期 1, 页码 34-40出版社
BENTHAM SCIENCE PUBL
DOI: 10.2174/18715273113126660184
关键词
Akt; Brain-Derived Neurotrophic Factor; Down's syndrome; local translation; mammalian Target of Rapamycin; rapamycin; trisomy 21; Ts1Cje
资金
- Ministerio de Economia y Competitividad (Instituto de Salud Carlos III, Spain) [PI110507]
- Junta de Andalucia [P09-CTS-4610]
- Fondation Jerome Lejeune (France)
An increasing amount of evidence suggests that the dysregulation of the Akt-mTOR (Akt-mammalian Target Of Rapamycin) signaling network is associated with intellectual disabilities, such as fragile X, tuberous sclerosis and Rett's syndrome. The Akt-mTOR pathway is involved in dendrite morphogenesis and synaptic plasticity, and it has been shown to modulate both glutamatergic and GABAergic synaptic transmission. We have recently shown that the Akt-mTOR pathway is hyperactive in the hippocampus of Ts1Cje mice, a model of Down's syndrome, leading to increased local dendritic translation that could interfere with synaptic plasticity. Rapamycin and rapalogs are specific inhibitors of mTOR, and some of these inhibitors are Food and Drug Administration-approved drugs. In this review, we discuss the molecular basis and consequences of Akt-mTOR hyperactivation in Down's syndrome, paying close attention to alterations in the molecular mechanisms underlying synaptic plasticity. We also analyze the pros and cons of using rapamycin/rapalogs for the treatment of the cognitive impairments associated with this condition.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据